Investors & Media


  • Item Type:
  • Year:
  • 17 Nov. 2012

    Kamada reports juvenile diabetes success

    The company says that its AAT protein may halt the progression of the disease.

  • 17 Nov. 2012

    Kamada reports type-1 diabetes success

    Kamada presents positive results of measurements of efficacy and safety in a unique clinical trial, for the treatment of type 1 (juvenile onset) diabetes, with its Alpha-1 Antitrypsin (AAT) protein.

  • 6 Nov. 2012

    Kamada announces today its financial results for the third quarter and the first 9 months of 2012

    Revenues at $17.7 million,
    Operating profit at $1.3 million.
    An increase of 33% in revenues in the first 9 months of 2012 to $51 million.
    An increase of 39% in Kamada's manufactured products sector revenues in the first 9 months of 2012 to approximately $30.5 million.
    Annual revenues forecast of $72 million reflects continued growth and record revenues forecast for Q4 of 2012.

  • 4 Nov. 2012

    Kamada: Trial shows Glassia effective against lung disease

    Drug developer Kamada Ltd. (TASE: KMDA) today announced positive results in a preclinical trial of its Alpha-1 Antitrypsin (AAT) protein, the active ingredient in its drug, Glassia, which may promote the company's diabetes activity and help it enter other fields.

  • 4 Nov. 2012

    Kamada Announces New Data on its Glassia Drug Supporting its Diabetes Activities and Treatment of Additional Therapeutic Indications

    The AAT Protein in Kamada's Glassia Drug Shows Promise in a Series of Studies that Demonstrate Prevention of Lung Infection and Successful Organ Transplantation:
    In several pre-clinical studies performed in Ben Gurion University, lead by Dr Eli Lewis, the Glassia drug by Kamada shows new therapeutic capabilities including being a potential treatment to bacterial lung infection, serving as a strog anti inflammatory agent in COPD and prevention of transplant rejection.
    Furthermore, results of Glassia phase 2 study in Type 1 Diabetes (T1D) are expected to be published during the course of this month.

  • 21 Oct. 2012

    Kamada Completes Patient Recruitment for its Phase II/III clinical trial with Inhaled AAT for Treating Alpha-1 Deficiency

    Completion of recruitment was upon meeting the statistical data collection goals required for the study efficacy measures.
    The trial will be completed during Q4 2013.
    EMA supports Kamada in an open label extension treatment for patients who have completed their trial participation.
    David Tsur, Kamada CEO: Completing patient recruitment is a significant achievement for Kamada, further strengthening its position as a global leader in developing the inhaled Alpha-1 antitrypsin”.

  • 18 Oct. 2012

    Kamada is among the 2012 Technology Fast 50 Winners

    The Deloitte Technology Fast 50, one of Israel's foremost technology award programs.
    It annually recognizes and honors the 50 private and publicly-held fastest growing technology companies in Israel, based on percentage revenue growth over a five-year period.
    The Fast 50 program honors business growth, technological innovation and Israel entrepreneurial spirit.
    The Technology Fast 50 is part of a national and international program run by Deloitte.

  • 14 Oct. 2012

    Kamada wins FDA approval for Phase II/III emphysema study

    The company's AATD-IH drug could become the first inhalable treatment for congenital emphysema.

  • 14 Oct. 2012

    Kamada receives FDA Approval to its IND for Phase II Clinical Trial of Inhaled Alpha-1 Antitrypsin Deficiency (AATD-IH) in the US

    Kamada is currently evaluating strategic collaborations for conducting the Phase II clinical trial in the US.

    The Phase II/III trial of AATD-IH, which is already underway in Europe and its results are expected late 2013, may serve the drug approval application to FDA, together with the data from the Phase II study of this IND Approval .

  • 7 Aug. 2012

    Kamada in distribution deal with Chiesi for Europe, Turkey and former CIS countries

    Israeli biopharma company Kamada (KMDA: TA) has entered into an exclusive agreement with privately-owned Italian drugmaker Chiesi Farmaceutici for the distribution of its breakthrough inhaled alpha-1 antitrypsin for treatment of alpha-1 antitrypsin deficiency (AATD-IH), a genetic disorder.